Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2012 05:56 ET | Source: Exiqon A/S

Registrering af kapitalforhøjelse gennemført

I forlængelse af fondsbørsmeddelelse nr. 10/2012 kan det herved meddeles, at kapitalforhøjelsen på 1.805.056 stk. nye aktier à nominelt DKK 1 i dag er registreret i Erhvervsstyrelsen. Efter...
June 27, 2012 05:56 ET | Source: Exiqon A/S

Registration of capital increase completed

With reference to Announcement No. 10/2012 we are pleased to announce that the capital increase of 1,805,056 new shares with a nominal value of DKK 1 each was registered with the Danish Business...
June 22, 2012 05:00 ET | Source: Exiqon A/S

Exiqon A/S completes directed issue of 1,805,056 new shares at market price

The Supervisory Board of Exiqon A/S (NASDAQ OMX Copenhagen A/S: “EXQ”) has today completed the directed issue of 1,805,056 new shares of DKK 1 nominal value through an accelerated book-building...
June 22, 2012 05:00 ET | Source: Exiqon A/S

Exiqon A/S gennemfører rettet emission af 1.805.056 nye aktier til markedskurs

Bestyrelsen for Exiqon A/S (NASDAQ OMX Copenhagen A/S: “EXQ”) har i dag gennemført en rettet emission af 1.805.056 nye aktier à nominelt DKK 1 gennem en såkaldt accelereret bookbuilding-proces. For...
June 22, 2012 04:26 ET | Source: Exiqon A/S

Exiqon A/S udbyder op til 1.805.056 nye aktier i en rettet emission til markedskurs

Bestyrelsen for Exiqon A/S (NASDAQ OMX Copenhagen A/S: “EXQ”) har i dag besluttet at udbyde op til 1.805.056 nye aktier à nominelt DKK 1 til markedskurs gennem en såkaldt accelereret...
June 22, 2012 04:26 ET | Source: Exiqon A/S

Exiqon A/S launches a directed issue of up to 1,805,056 new shares at market price

The Supervisory Board of Exiqon A/S (NASDAQ OMX Copenhagen A/S: “EXQ”) has today resolved to launch a directed issue of up to 1,805,056 new shares of DKK 1.00 nominal value at market price through...
June 14, 2012 08:33 ET | Source: Exiqon A/S

Exiqon lancerer unikt bioinformatisk software tool til design og udvælgelse af LNA™-forbedrede qPCR assays til kombineret analyse af messenger RNA, microRNA og andre ncRNA.

Exiqon A/S (NASDAQ OMX: “EXQ”), en førende leverandør af højt specialiserede produkter til genanalyse, offentliggjorde i dag lanceringen af et unikt nyt ’state-of-the-art’ online tool til design af...
June 14, 2012 08:33 ET | Source: Exiqon A/S

Exiqon offers unique bioinformatics tool for design and selection of LNA™ enhanced qPCR assays for combined analysis of messenger RNA, microRNA and other ncRNA.

Exiqon A/S (NASDAQ OMX: “EXQ”), a leading supplier of high-value gene expression analysis products, today announced the launch of a new unique state-of-the-art online tool for design of LNA™...
June 01, 2012 14:00 ET | Source: Exiqon A/S

Prognostisk betydning af microRNA-21 påvist i en stor, unik populationsbaseret gruppe af patienter med tyktamskræft i stadie II ved hjælp af LNA™-baseret in situ hybridization (ISH).

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) offentliggjorde i dag publiceringen af data på ASCO’s årsmøde 2012 fra et kliniske studie baseret på LNA™-hybridisering i væv, der omfatter alle...
June 01, 2012 14:00 ET | Source: Exiqon A/S

Prognostic importance of microRNA-21 demonstrated in a unique, large population-based cohort of stage II colon cancer patients using LNA™ based in situ hybridization (ISH).

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the presentation of data, using the company’s proprietary LNA™ based in situ hybridization (ISH), from a clinical study including all stage...